NCT01764477 - Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions

Advanced Pancreatic CancerMetastatic Pancreatic CancerPancreatic Adenocarcinoma

Interventions

DRUG

PRI-724

"Gemcitabine: 1000 mg/m2 IV over 30 minutes; once weekly dosing; 3 weeks on with 1 week recovery (4 weeks per cycle)~PRI-724:~Cohort 1: 320 mg/m2/day; Cohort 2: 640 mg/m2/day; Cohort 3: 905 mg/m2/day; Continuous IV over 24 hours; daily x 7 days; 1 week on with 1 week recovery × 2 (4 weeks per cycle)"

Trial Locations (5)

55905

Mayo Clinic, Rochester

90033

USC Norris Comprehensive Cancer Center, Los Angeles

94115

University of California, San Francisco, San Francisco

98109

University of Washington Seattle Cancer Care Alliance, Seattle

02114

Massachusetts General Hospital Cancer Center, Boston